1,1-diethylbiguanide | 44976-13-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,1-diethylbiguanide
• 英文别名: N,N-diethylimidodicarbonimidic diamide；N¹,N¹-Diethylbiguanid；1,1-Diaethyl-biguanid；N.N-Diaethyl-N'-guanyl-guanidin；ω.ω-Diaethyl-biguanid；N,N-Diethyl-Imidodicarbonimidic diamide；3-(diaminomethylidene)-1,1-diethylguanidine
• CAS: 44976-13-8
• 化学式: C₆H₁₅N₅
• 分子量: 157.219
• InChiKey: RTTNMYWPMMYGIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  91.5
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,1-diethylbiguanide 、 alkaline earth salt of/the/ methylsulfuric acid 生成 二乙胺
  参考文献：
  名称：

  Emich, Monatshefte fur Chemie, 1891, vol. 12, p. 20

  摘要：

  DOI：
• 作为产物：
  描述：

  二乙胺 、 二聚氰胺 在 盐酸 作用下， 以 甲苯 、 水 为溶剂， 反应 5.25h， 以37%的产率得到1,1-diethylbiguanide
  参考文献：
  名称：

  Synthesis and In Vitro AMPK Activation of Cycloalkyl/Alkarylbiguanides with Robust In Vivo Antihyperglycemic Action

  摘要：

  这项工作描述了设计、一步合成以及一系列十种脂环和芳香（烷基+芳基：烷芳基）双胍类似物（与二甲双胍和苯乙双胍类似物）的体外、体内和体外抗糖尿病评价。设计是通过同位素替代、链环转化以及较低和较高同系物策略构思的。所有化合物均以晶体形式获得，并根据其光谱数据（NMR和质谱）确认了其结构，通过微量分析确定了其纯度。化合物在体外被评估为AMP激活蛋白激酶（AMPK）的激活剂。结果表明，化合物4、5和6与二甲双胍相比显示出类似或甚至更好的效果。使用AMPK的调节亚基γ进行对接分析，显示出与核苷酸结合口袋的多个相互作用。在小鼠糖尿病实验模型中，对化合物4-6进行了50mg/kg的单剂量体内评价。结果显示血浆葡萄糖水平显著下降（-40%）。选择化合物6进行口服葡萄糖耐量试验，显示出与二甲双胍类似的抗高血糖效果。体内结果表明，化合物4-6可能有效治疗实验性T2DM。

  DOI：

  10.1155/2017/1212609

文献信息

• 3-deoxyglucosone and skin
  申请人：——

  公开号：US20030219440A1

  公开（公告）日：2003-11-27

  The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.

  该发明涉及一种从皮肤中去除3-去氧葡萄糖酮和其他α-二酮糖的方法。该发明还涉及抑制皮肤中3-去氧葡萄糖酮和其他α-二酮糖的产生和功能的方法。该发明还涉及治疗与皮肤相关的3-去氧葡萄糖酮和其他α-二酮糖相关疾病和障碍的方法。
• PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT
  申请人：THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

  公开号：US20170333370A1

  公开（公告）日：2017-11-23

  The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-α, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.

  本发明涉及一种大叶腺苷衍生物化合物，能够有效预防和治疗免疫性疾病。根据本发明的大叶腺苷衍生物化合物抑制了炎性细胞因子IL-17和TNF-α的产生，增加了具有免疫调节功能的调节性T细胞的活性，并在动物模型中展现出优秀的治疗效果。因此，这种基于大叶腺苷衍生物的化合物可以用作免疫抑制剂或药物组合物，能够预防或治疗由免疫反应失调引起的各种免疫性疾病，如自身免疫性疾病、炎症性疾病和移植排斥等。
• Fructoseamine 3 kinase and the formation of collagen and elastin
  申请人：Tobia Annette

  公开号：US20070065443A1

  公开（公告）日：2007-03-22

  The invention relates to the discovery that levels of collagen and elastin can be modulated by changing the flux through the Amadori Pathway and that copper containing compounds and complexes inhibit the enzyme fructoseamine-3-kinase.

  本发明涉及到一项发现，即通过改变Amadori途径的通量可以调节胶原蛋白和弹性蛋白的水平，并且含铜化合物和配合物可以抑制酶果糖胺-3-激酶。
• Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
  申请人：Brown R. Truman

  公开号：US20060089316A1

  公开（公告）日：2006-04-27

  Disclosed are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels in high fructose corn syrop so that the high fructose corn syrup is less likely to induce tumor formation.

  公开了使用各种已知与3-脱氧葡萄糖酮（3DG）或其前体结合的化合物的方法，以减少对肿瘤形成的易感性和/或预防或延迟由3DG及其前体诱导的肿瘤形成。还公开了降低高果糖玉米糖浆中3DG水平的方法，以使高果糖玉米糖浆不太可能诱导肿瘤形成。
• CURABLE-ON-DEMAND COMPOSITION COMPRISING DUAL REACTIVE SILANE FUNCTIONALITY
  申请人：Yang Yu

  公开号：US20130178553A1

  公开（公告）日：2013-07-11

  A curable composition comprises (a) at least one inorganic or organic compound comprising reactive silane functionality comprising at least one hydrosilyl moiety; (b) at least one inorganic or organic compound comprising reactive silane functionality comprising at least one hydroxysilyl moiety, the hydroxysilyl moiety optionally being generated in situ by hydrolysis of at least one hydrosilyl moiety; and (c) at least one photoactivatable composition that, upon exposure to radiation, generates at least one base selected from amidines, guanidines, phosphazenes, proazaphosphatranes, and combinations thereof; with the proviso that, when component (a) is an organic polymer, then component (b) is different from component (a) and is not generated in situ by hydrolysis of component (a).

  一种可治愈的组合物包括：（a）至少一种含有反应性硅烷官能团的无机或有机化合物，其中硅烷官能团包括至少一个氢硅烷基；（b）至少一种含有反应性硅烷官能团的无机或有机化合物，其中硅烷官能团包括至少一个羟基硅烷基，羟基硅烷基可以通过至少一个氢硅烷基的水解而在原位生成；以及（c）至少一种光活性组合物，当暴露于辐射下时，生成至少一种从氨基甲酸酰胺、鸟嘌呤、磷氮烷、丙氨酸磷酸酯和其组合物中选择的碱，前提是当组分（a）是有机聚合物时，组分（b）与组分（a）不同，并且不是通过组分（a）的水解在原位生成的。